Literature DB >> 29146309

StarD13 3'-untranslated region functions as a ceRNA for TP53INP1 in prohibiting migration and invasion of breast cancer cells by regulating miR-125b activity.

Lufeng Zheng1, Xiaoman Li2, Jinjiang Chou1, Chenxi Xiang1, Qianqian Guo1, Zhiting Zhang1, Xinwei Guo1, Lanlan Gao1, Yingying Xing1, Tao Xi3.   

Abstract

Competitive endogenous messenger RNA (ceRNA) affects transcription of other RNA molecules by competitively binding common microRNAs. Previous studies have shown that TP53INP1 functions as a suppressor in tumor metastasis. Our study elucidated StarD13 messenger RNA as a ceRNA in regulating migration and invasion of breast cancer cells. MicroRNA-125b was identified to induce metastasis of MCF-7 cells and bind with both StarD13 3'UTR and TP53INP1 3'UTR. Therefore, a ceRNA interaction between StarD13 and TP53INP1 mediated by competitively binding to miR-125b was indicated. Importantly, a microRNA-125b binding site at 4546-4560 nt on StarD13 was verified more vital for this ceRNA interaction. Indirectly regulation of SPARC in inducing metastasis of breast cancer cells by StarD13 via competitively binding with TP53INP1 was further confirmed. In conclusion, our findings demonstrate a ceRNA regulatory network which could give a better understanding of metastatic mechanisms of breast cancer.
Copyright © 2017 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Invasion; Migration; StarD13; TP53INP1; ceRNA

Mesh:

Substances:

Year:  2017        PMID: 29146309     DOI: 10.1016/j.ejcb.2017.11.002

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  9 in total

1.  StarD13 differentially regulates migration and invasion in prostate cancer cells.

Authors:  Leila Jaafar; Isabelle Fakhoury; Sahar Saab; Layal El-Hajjar; Wassim Abou-Kheir; Mirvat El-Sibai
Journal:  Hum Cell       Date:  2021-01-09       Impact factor: 4.174

2.  DLC2 operates as a tumor suppressor gene in breast cancer via the RhoGTPase pathway.

Authors:  Zheng Yang; Hanrui Chen; Man Shu; Yunjian Zhang; Ling Xue; Yuan Lin
Journal:  Oncol Lett       Date:  2018-12-28       Impact factor: 2.967

Review 3.  The Emerging Roles of miR-125b in Cancers.

Authors:  Ying Wang; Guilin Zeng; Yicheng Jiang
Journal:  Cancer Manag Res       Date:  2020-02-12       Impact factor: 3.989

4.  MMP1 3'UTR facilitates the proliferation and migration of human oral squamous cell carcinoma by sponging miR-188-5p to up-regulate SOX4 and CDK4.

Authors:  Chengyong Wang; Chuanqing Mao; Yongzhen Lai; Zhiyu Cai; Weihui Chen
Journal:  Mol Cell Biochem       Date:  2020-10-22       Impact factor: 3.396

5.  NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer.

Authors:  Yueyue Wang; Lei Yan; Lingyu Zhang; Henan Xu; Tiantian Chen; Yu Li; Haifeng Wang; Sulian Chen; Wenrui Wang; Changjie Chen; Qingling Yang
Journal:  Int J Oncol       Date:  2018-07-09       Impact factor: 5.650

6.  Robust analysis of novel mRNA-lncRNA cross talk based on ceRNA hypothesis uncovers carcinogenic mechanism and promotes diagnostic accuracy in esophageal cancer.

Authors:  Li-Ping Chen; Hong Wang; Yi Zhang; Qiu-Xiang Chen; Tie-Su Lin; Zong-Qin Liu; Yang-Yang Zhou
Journal:  Cancer Manag Res       Date:  2018-12-27       Impact factor: 3.989

7.  CFIm25-regulated lncRNA acv3UTR promotes gastric tumorigenesis via miR-590-5p/YAP1 axis.

Authors:  Kai Liu; Ben-Jun Wang; WeiWei Han; Chun-Hua Chi; Chao Gu; Yu Wang; Xiaohai Fu; Wei Huang; Zhiguo Liu; Xilin Song
Journal:  Oncogene       Date:  2020-02-17       Impact factor: 9.867

8.  Tanshinone IIA attenuates the stemness of breast cancer cells via targeting the miR-125b/STARD13 axis.

Authors:  Xiaoman Li; Qi Jia; Yinyin Zhou; Xuan Jiang; Li Song; Yuanyuan Wu; Aiyun Wang; Wenxing Chen; Shijun Wang; Yin Lu
Journal:  Exp Hematol Oncol       Date:  2022-01-20

9.  Transmembrane protein TMEM119 facilitates the stemness of breast cancer cells by activating Wnt/β-catenin pathway.

Authors:  Ben Yang; Fengling Wang; Gang Zheng
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.